Form 4: Avalo Therapeutics Director June Sherie Almenoff Acquires Stock Options and Restricted Stock Units

Director June Sherie Almenoff acquired stock options for 24,600 shares and 9,500 restricted stock units in Avalo Therapeutics, Inc.

Summary

• On August 13, 2024, June Sherie Almenoff, a director of Avalo Therapeutics, Inc. (AVTX), acquired stock options and restricted stock units (RSUs).
• Almenoff acquired options to purchase 24,600 shares of common stock at an exercise price of $9.88 per share, which expire on August 13, 2034.
• She also acquired 9,500 RSUs, each representing a contingent right to receive one share of common stock upon vesting.
• Both the stock options and RSUs vest in three equal installments on March 28, 2025, March 28, 2026, and March 28, 2027, contingent upon continued service.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The granting of stock options and RSUs is a standard practice, indicating confidence in the company's future, but it's not a major event.

Positives

• The acquisition of stock options and RSUs by a director signals confidence in the company's future performance.
• The vesting schedule incentivizes continued service and alignment with long-term company goals.

Future Outlook

The vesting schedule of the stock options and RSUs suggests an expectation of continued service and contribution from the director over the next three years.

Industry Context

Stock options and RSUs are common forms of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Granting stock options and RSUs to directors is a standard practice in the biotech industry to incentivize performance and align interests with shareholders.
• Comparable companies like BioNTech or Moderna also use similar equity-based compensation plans for their executives and directors.

Stakeholder Impact

• The granting of stock options and RSUs aligns the director's interests with those of shareholders, potentially leading to decisions that benefit the company's long-term value.
• Employees may view this as a positive sign, indicating the company's commitment to its leadership.

Key Dates